Last Updated: May 27, 2026

Dutasteride - Generic Drug Details

Name: dutasteride Generic Launch, Drug Patent, and Exclusivity Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for dutasteride and what is the scope of patent protection?

Dutasteride is the generic ingredient in four branded drugs marketed by Waylis Therap, Acella, Actavis Labs Fl Inc, Adaptis, Amneal Pharms, Apotex, Ascent Pharms Inc, Aurobindo Pharma Ltd, Barr, Chartwell, Heritage Pharms Inc, Hikma, Humanwell Puracap, Onesource Specialty, Ph Health, Pharmobedient, Rising, Strides Pharma, Zydus Lifesciences, Aurobindo Pharma, and Zydus Pharms, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for dutasteride. Thirteen suppliers are listed for this compound.

Summary for dutasteride

US Patents:	0
Tradenames:	4
Applicants:	21
NDAs:	25
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	92
Clinical Trials:	116
Patent Applications:	7,275
Drug Prices:	Drug price trends for dutasteride
What excipients (inactive ingredients) are in dutasteride?	dutasteride excipients list
DailyMed Link:	dutasteride at DailyMed

See drug prices for dutasteride

Drug Sales Revenue Trends for dutasteride

See drug sales revenues for dutasteride

Recent Clinical Trials for dutasteride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chong Kun Dang Pharmaceutical	PHASE3
EMS	PHASE3
Bio-innova Co., Ltd	PHASE1

See all dutasteride clinical trials

Pharmacology for dutasteride

Drug Class	5-alpha Reductase Inhibitor
Mechanism of Action	5-alpha Reductase Inhibitors

Medical Subject Heading (MeSH) Categories for dutasteride

5-alpha Reductase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for dutasteride

G04CB	Testosterone-5-alpha reductase inhibitors
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for DUTASTERIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVODART	Capsules	dutasteride	0.5 mg	021319	1	2007-10-29

US Patents and Regulatory Information for dutasteride

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	202509-001	Feb 26, 2014	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Pharms	DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	207769-001	May 24, 2018	AB	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Lifesciences	DUTASTERIDE	dutasteride	CAPSULE;ORAL	204373-001	Oct 4, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmobedient	DUTASTERIDE	dutasteride	CAPSULE;ORAL	203241-001	Jun 14, 2016		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Actavis Labs Fl Inc	DUTASTERIDE	dutasteride	CAPSULE;ORAL	202808-001	Nov 20, 2015		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for dutasteride

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Waylis Therap	AVODART	dutasteride	CAPSULE;ORAL	021319-001	Nov 20, 2001	⤷ Start Trial	⤷ Start Trial
Waylis Therap	AVODART	dutasteride	CAPSULE;ORAL	021319-001	Nov 20, 2001	⤷ Start Trial	⤷ Start Trial
Waylis Therap	AVODART	dutasteride	CAPSULE;ORAL	021319-001	Nov 20, 2001	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.